NASDAQ: EXAS 67.31
-0.54 -0.8% Minimum 20 min delay
2:15 PM ET on Dec 14, 2018
Volume: 762,157
NASDAQ: EXAS 67.31
-0.54 -0.8% Minimum 20 min delay
2:15 PM ET on Dec 14, 2018
Volume: 762,157

Exact Sciences Statement Regarding Pending USPSTF Colorectal Cancer Screening Guidelines

06/15/2016

MADISON, Wis., June 15, 2016 /PRNewswire/ -- Exact Sciences (Nasdaq: EXAS) issued the following statement today: "We are aware that the U.S. Preventive Services Task Force's final colorectal cancer screening guidelines are anticipated to be issued in the near future.  Exact Sciences will comment on the guidelines once they are released by the task force or published in the Journal of the American Medical Association." 

Exact Sciences Corporation Logo (PRNewsFoto/EXACT SCIENCES CORPORATION)

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please follow us on Twitter @ExactSciences or find us on Facebook.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and health care providers; the willingness of health insurance companies and other payors to reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of any healthcare reforms, including without limitation the Affordable Care Act, or changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and/or quality-of-care metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative and licensing arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; the impact of our nationwide television advertising campaign; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 

Logo - http://photos.prnewswire.com/prnh/20160108/320353

Contact: J.P. Fielder
Senior Director, Corporate Communications
jpfielder@exactsciences.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/exact-sciences-statement-regarding-pending-uspstf-colorectal-cancer-screening-guidelines-300285049.html

SOURCE EXACT SCIENCES CORP